Evotec SE ADR (EVO)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Evotec SE ADR (EVO) is down 14.9% since the beginning of the year. At $3 per share, EVO is trading 40.7% below its 52-week high of $4. Investors who bought $1,000 worth of EVO shares 5 years ago would now be looking at an investment worth $120.

Evotec SE ADR (EVO) has returned -14.94% so far this year and -30.32% over the past 12 months. Over the last ten years, EVO has returned 2.48% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Dec 4, 2009, EVO's average daily return is +0.06%, while the average monthly return is +1.10%. At this rate, an investment would double in approximately 5.3 years.

Historically, 50% of months were positive and 50% were negative. The best month was Aug 2017 with a return of +33.0%, while the worst month was Jan 2024 at -34.0%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 4 months.

On a daily basis, EVO closed higher 38% of trading days. The best single day was Apr 6, 2011 with a return of +20.2%, while the worst single day was Apr 24, 2024 at -31.6%.

Evotec SE ADR has an annualized alpha of 4.34%, beta of 0.82, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since December 04, 2009.

• This stock participated in 149.93% of S&P 500 Index downside but only 110.02% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

EVO ranks 18 for risk / return — in the bottom 18% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Evotec SE ADR. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Evotec SE ADR was 91.29%, occurring on Mar 13, 2026. The portfolio has not yet recovered.

The current Evotec SE ADR drawdown is 90.12%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Evotec SE ADR over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Evotec SE ADR is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.